hsa-mir-640: Hsa-mir-640 is a microRNA that has been found to be downregulated in bile samples of patients with primary sclerosing cholangitis (PSC) and PSC/cholangiocarcinoma (CCA) [PMC5223017]. It is also one of the miRNAs that were not profiled in certain signatures [PMC4519802]. Hsa-mir-640 has been shown to have a minimum degree of regulation and only targets a small number of genes [PMC3189221]. Although hsa-mir-640 has been found to be deregulated in several cancers, it is not the most abundant isoform and its characterization is still limited [PMC4210590]. In glioblastoma, hsa-mir-640 has been identified as a key miRNA [PMC7798089]. In silico analysis suggests that hsa-mir-640 may have binding sites within mutated loci in AKT2, CTNNB1, and ERBB2 genes [PMC3334977]. Hsa-mir-640 has also been identified as one of the miRNAs that may bind to circ_0006677 [PMC8155686]. It is part of a group of miRNAs that show significantly higher expression in certain clusters compared to others [PMC3672661]. Hsa-mir-640 has been found to be deregulated by simvastatin treatment in HUVEC cell culture [PMC8415262]. Functional enrichment analysis suggests that hsa-mir-640 may be involved in neurotrophin-related signaling pathways and nervous system development [PMC6036758]. In seminoma, hsa-mir-640 is downregulated and its target gene MKI67 is associated with mTOR pathway [PMC6797975]. Lastly, hsa-miR-640 has been identified as one of the miRNAs that can bind to certain circRNAs [PMC8351580].